Belite Bio Inc - ADR

NASDAQ:BLTE   3:59:59 PM EDT
32.32
-0.70 (-2.12%)
7:38:28 PM EDT: $32.00 -0.32 (-0.99%)
Products, Regulatory

Belite Bio Finalizes Phase 3 Clinical Trial Plans For Advanced Dry AMD Treatment With Tinlarebant (LBS-008)

Published: 11/18/2022 13:21 GMT
Belite Bio Inc - ADR (BLTE) - Belite Bio Finalizes Phase 3 Clinical Trial Plans for Advanced Dry Amd Treatment With Tinlarebant (lbs-008).
Belite Bio - Tinlarebant Granted Fast Track Designation, Rare Pediatric Disease Designation in U.S., Orphan Drug Designation in U.S., Europe for Stgd1.
Belite Bio Inc - 12-month Interim Data From Ongoing Phase 2 Stgd1 Study Continues to Show Halting Or Slowing of Lesion Growth.
Belite Bio Inc - Global Phase 3 Study in Adolescent Stgd1 Patients ( "dragon" Study) is Recruiting Subjects.
Belite Bio Inc - a 2-year Phase 2 Study in Adolescent Stgd1 Patients is Ongoing.